HTB homepage • Conference reports • Articles by subject • Subscribe August 2016 Contents Editorial July/August 2016: Volume 17 Number 7/8 Conference reports 21st International AIDS Conference (AIDS 2016), 18-22 July 2016, Durban, South Africa AIDS 2016: online access to conference programme ZERO: no linked HIV transmissions in PARTNER study after couples had sex 58,000 times without condoms ZERO HIV transmissions in PARTNER study: most widely reported i-Base article PrEP studies at AIDS 2016: includes first preclinical data with EFdA Dual therapy with dolutegravir + 3TC keep viral load undetectable: 48 week results from PADDLE study Once-daily raltegravir at last available: 48 week results from ONCEMRK study Dual long-acting cabotegravir plus rilpivirine injections: 48-week results from LATTE-2 Dolutegravir is superior to boosted atazanavir in women in the ARIA study PROMISE results support WHO recommendations for pregnant and breastfeeding women: more needs to be done to improve ART acceptability and adherence Sub-Saharan African countries moving quickly to recommend “Treat All” Efavirenz associated with suicide risk in analysis from START study CD4:CD8 ratio is more sensitive marker of risk than CD4 counts in analysis from START study Treatment in primary HIV infection is significantly more likely to normalise CD4:CD8 ratio Publications launched at AIDS 2016 8th International Workshop on HIV paediatrics, 15-16 July 2016, Durban, South Africa. No increased resistance with once daily dosing of abacavir and 3TC than twice daily dosing in the ARROW trial TB 2016, 16-17 July 2016, Durban, South Africa Universal treatment of multi-drug resistant TB is possible within current budgets with generic production Shortened nine-month MDR-TB treatment works well in children and adolescents Levofloxacin: safety and tolerability in HIV positive and negative children treated for MDR-TB 2016 Towards an HIV Cure Symposium, 16-17 July 2016, Durban, South Africa 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, 8-10 June 2016, Washington DC, USA Modelling data might support use of low dose 400 mg efavirenz in pregnancy Pharmacokinetics of antiretrovirals comparable to that in non-pregnant women from three weeks after delivery Guidelines BHIVA antiretroviral guidelines updated (2016) HIV prevention and transmission PROUD study closes leaving participants without access to PrEP EMA overcomes its own prejudice to approve PrEP in Europe: four years too late NAT legal challenge forces NHS England to reopen process for PrEP: 45-day public consultation now online Two large PrEP studies using two-month infusion of antibodies to prevent HIV infection: oral PrEP included for all participants PDFs July/August 2016: Volume 17 Number 7/8 HTB homepage • Conference reports • Articles by subject • Subscribe
